

### Nivolumab ; 纳武单抗

产品编号 : MB2767

质量标准 : >95%,蛋白原液

包装规格 : 1MG/5MG

产品形式 :

#### 基本信息

|        |   |
|--------|---|
| 分子式    | N/A   |
| 分子量    | 143.59KD  |
| CAS NO | 946414-94-4   |
| 储存条件   | -70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light |

**简介:** Nivolumab 是一种 PD-1 抗体类抑制剂, 用于晚期 (转移性) 非小细胞肺癌的研究。

**产品形式:** 蛋白原液。每种装于冻存管中, 单抗质量为标示数量 1MG 或者 5MG, 体积根据其浓度不同略有不同。

#### 质量标准:

Non-reduced CE-SDS:.....>90%;

SEC-HPLC:.....>95%;

Bacterial Endotoxins Test: .....<10EU/ml

Residual Proteins of HostCell: .....<100 ng/mg

Exogenous residual DNA: .....<100pg/mg

Residual Protein A: .....<100 ng/mg

Biological Activity:.....80% to 125% of standard

**储存条件:** -70 ± 15°C for long-term storage, 2-8°C for short-term storage, away from light.

#### 使用建议:

meilunbio 提供的产品为蛋白原液形式。每种装于冻存管中, 单抗质量为标示数量 1MG 或者 5MG, 体积根据其浓度不同略有不同。

使用前可以根据自己实验需求进行稀释, 溶剂建议用去离子无菌水(meilunbio 货号 MA0028, 去离子无菌水(细胞培养用水))或者 PBS (meilunbio 货号 MA0015PBS(1X),细胞培养级)。

不建议使用含有防腐成分的稀释液进行稀释, 会增加细胞或者动物毒性。

稀释前, 计算加入多少体积溶剂, 请参考购买批次质检单上蛋白浓度, 或者询问我司,

举例, 质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml

对应 5MG 包装的蛋白原液体积为 5mg (质量) /50mg/ml(浓度)=0.1ML,

实验需求蛋白浓度为 10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入 0.4ML, 即 400ul PBS 或者无菌去离子水即可。

若给药量为固定质量值, 比如单次给药 0.5MG, 对应蛋白原液给药体积为 10ul, 建议稀释后, 提高给药体积降低误差, 因为注射器或者移液器吸头残留会影响实验效果。

稀释后的蛋白溶液, 可于 2-8 度冷藏避光保存不超过 2 周, 不建议长期储存。

避免反复冻融, 每次冻融蛋白活性会降低约 5%左右。

**生物活性 (仅来自于公开文献, 不保证其有效性)**

|           |  |
|-----------|--|
| <b>描述</b> | Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.   |
| <b>靶点</b> | PD-1   |
| <b>体外</b> | Nivolumab binds to CHO cells expressing PD-1 with an EC50 of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC50 of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus                    |
| <b>体内</b> | Nivolumab (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted. |

**美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)**

| 产品编号   | 品名.          | Target      |
|--------|--------------|-------------|
| MB2806 | aflibercept  | VEGFR       |
| MB2786 | Alemtuzumab  | CD52        |
| MB2787 | Alirocumab   | PCSK9       |
| MB2789 | Avelumab     | PDL-1       |
| MB2790 | Atezolizumab | PDL-1       |
| MB2791 | Bevacizumab  | VEGF        |
| MB2792 | Cetuximab    | EGFR        |
| MB2803 | Daratumumab  | CD38        |
| MB2794 | Denosumab    | RANK Ligand |
| MB2023 | Eculizumab   | 补体蛋白(C5)    |
| MB2795 | Etanercept   | TNF         |

|        |                       |               |
|--------|-----------------------|---------------|
| MB2797 | Evolocumab            | PCSK9         |
| MB2773 | Infliximab            | TNF- $\alpha$ |
| MB2769 | Ipilimumab            | CTLA-4        |
| MB2772 | Matuzumab             | EGFR          |
| MB2766 | Mepolizumab           | IL-5          |
| MB2784 | Adalimumab            | TNF- $\alpha$ |
| MB2774 | Obinutuzumab          | CD20          |
| MB2776 | Ofatumumab            | CD20          |
| MB2777 | Omalizumab            | IgE           |
| MB2781 | Panitumumab           | EGFR          |
| MB2761 | Pembrolizumab         | PD-1          |
| MB2762 | Pertuzumab            | HER2          |
| MB2763 | Ranibizumab           | VEGFR         |
| MB2938 | Ramucirumab           | VEGFR         |
| MB2749 | Rituximab             | CD20          |
| MB2757 | Secukinumab           | IL-17         |
| MB2751 | Tocilizumab/Atlizumab | IL-6 receptor |
| MB2753 | Trastuzumab           | ErbB2         |
| MB2758 | Ustekinumab           | IL-12         |

**用途及描述:** 仅供科研, 严禁用于人体(For R&D Only)